Looking at the raw numbers first: annual revenue has gone $13.1M (2022) → $12.0M (2023) → $10.8M (2024) → $7.1M (2025). That's not a "pre-profit growth" company — that's a shrinking research project. Meanwhile operating losses widened from -$68.5M to -$84.7M and net loss hit -$216M. The $44.9M cash balance against -$77M FCF means roughly 7 months of runway absent a raise, and the equity line being blank in the tile is itself a tell — they've almost certainly been issuing stock aggressively (consistent with the 333x P/S on a ~$6B cap against $7M revenue). The Q1 2026 print of $4.4M revenue and +$33M net income is almost certainly a non-cash mark — likely a warrant liability revaluation — not operational. The pattern of wildly oscillating NI (-$201M, then +$42M, then -$39M, then -$201M again, then +$33M) on flat ~$2M quarterly revenue screams derivative liability accounting, not a business.

The prior models are directionally right but I'd push harder. The classification engine tagging this "pre_profit_growth" with 0.8 confidence is wrong — there is no growth. Revenue CAGR is **-23.2%** over multiple years; this is pre-profit *decay*. The pre-flight model caught this ("revenue has been essentially flat... while losses accelerate") and the synthesis verdict ("Disconnected from Fundamentals") is correct, but the framing still flatters the company by entertaining a quantum-advantage probability. At a $6B cap on $7M of declining revenue, the implied EV/Revenue of ~963x isn't pricing 15-25% probability of quantum advantage — it's pricing meme-flow and retail call-option speculation on the word "quantum." IONQ trades richly too, but at least shows revenue growth; Rigetti shows the opposite. The market-forces "avoid entirely" call is the most honest output in the stack.

The contrarian case — and I'll steelman it — is that quantum is a binary, lottery-ticket asset class where revenue today is irrelevant because the payoff is a 2028-2032 enterprise quantum-cloud TAM measured in tens of billions, and Rigetti's superconducting stack plus DARPA/DoE contracts gives it optionality you can't DCF. Under that frame, $6B is just a call premium on a $50B+ outcome with maybe 10% probability. Fine — but two things break that case: (1) revenue is going the wrong direction while peers' is going up, which is evidence the call is going out-of-the-money, not in; (2) the insider tape is brutal — ten consecutive S-Sales from September 2025 through February 2026, zero buys, including 150K+ share clips in December right into strength. People with the technical read on whether quantum advantage is near are unloading. That's the opposite of what you'd see if a 2026-2027 commercialization inflection were real.

Where the data is thin: the balance sheet tile is missing debt and equity lines, and the Q1 2026 $33M "profit" needs the 10-Q footnotes to confirm it's warrant/derivative mark-to-market rather than operations (I'm 90% sure it is given the magnitude vs. revenue). Share count trajectory is also absent — critical for a serial diluter, because the $6B cap may reflect a share count that's ballooned 30-50% in 18 months. I'd want that before sizing any short, because squeeze risk in quantum names has been violent (RGTI itself ran from ~$1 to >$20 in a year). I dissent only mildly from the synthesis: it's not just "disconnected from fundamentals," it's actively deteriorating fundamentals against a rising valuation, which is a stronger statement. Fair value on a fundamentals-only basis is probably $1-3 (cash value plus modest IP option); fair value including narrative premium and quantum-sector beta is maybe $4-6. At $18 you're paying 3-4x even a generous narrative-adjusted value. Not a short I'd press without sizing for squeeze risk, but absolutely not a long, and the insider tape says the people who know are doing exactly what I'd do.